Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
|Videos|July 26, 2016
Emerging Therapies in ER+ Metastatic Breast Cancer
Author(s)Sarat Chandarlapaty, MD, PhD
Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
3
AI in Precision Oncology: A Paradigm Shift
4
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
5